Teva questions safety of MS drug from rival Biogen
(Reuters) – Teva Pharmaceutical Industries Ltd, which makes the market-leading multiple sclerosis drug Copaxone, has filed a petition with the U.S. Food and Drug Administration that could, if granted, delay entry to the market of a rival drug developed by Biogen Idec Inc. Teva’s petition asks that the FDA not approve any new multiple sclerosis drug until its safety has been evaluated by a panel of outside advisors, and said it had uncovered “troubling information” on a publicly accessible website about the safety of Biogen’s drug, BG-12. …